US Stock Insider Trading | NewAmsterdam Pharma disclosed three insider trading transactions on March 9

K-LinePoet · 2026-03-10T02:11:39+00:00

On March 9, 2026, NewAmsterdam Pharma disclosed multiple insider transactions, with Director Kastelein selling a total of approximately 306,000 shares, and Davidson selling over 440,000 shares in recent transactions, indicating the cash flow activity of insiders. The company focuses on developing new oral therapies for cardiovascular disease patients.

K-LinePoet

2026-03-10 02:11:39

Abstract generation in progress

On March 9, 2026, NewAmsterdam Pharma (NAMS) disclosed three insider trading transactions. Director Kastelein Johannes Jacob Pieter sold 104,500 shares on March 9, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 9, 2026	Director	Kastelein Johannes Jacob Pieter	March 6, 2026	Sell	94,100	30.32	2,853,800
March 9, 2026	Director	Kastelein Johannes Jacob Pieter	March 5, 2026	Sell	104,500	30.30	3,165,400
March 9, 2026	Director	Kastelein Johannes Jacob Pieter	March 9, 2026	Sell	101,400	30.29	3,071,700
March 2, 2026	Director	Davidson Michael H.	March 2, 2026	Sell	443,700	33.25	14,753,300
February 26, 2026	Director	Davidson Michael H.	February 25, 2026	Sell	46,500	35.11	1,633,200
February 26, 2026	Director	Davidson Michael H.	February 24, 2026	Sell	61,500	36.13	2,223,700
February 26, 2026	Director	Davidson Michael H.	February 24, 2026	Sell	3,161	36.46	115,300
February 26, 2026	Director	Davidson Michael H.	February 26, 2026	Sell	165,400	33.63	5,562,700
February 26, 2026	Director	Davidson Michael H.	February 25, 2026	Sell	10,400	35.96	375,300
February 26, 2026	Director	Davidson Michael H.	February 26, 2026	Sell	17,900	34.44	617,300

【Company Information】

NewAmsterdam Pharma Company N.V. was incorporated as a private limited company under Dutch law on October 17, 2019, under the name NewAmsterdam Pharma B.V. In October 2021, it was renamed NewAmsterdam Pharma Holding B.V. They are a clinical-stage biopharmaceutical company developing oral non-statin drugs for high-risk cardiovascular disease (CVD) patients with elevated residual low-density lipoprotein cholesterol (LDL-C or LDL), for whom existing therapies are insufficient or poorly tolerated. As an adjunct to statins, an effective, cost-efficient, and convenient LDL-lowering therapy is in significant unmet demand. Statins are the current standard of care for high-cholesterol high-risk CVD patients. Their lead candidate, obicetrapib, is a next-generation oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, currently in four Phase 3 and 2b clinical trials, as monotherapy and in combination with ezetimibe, aimed at lowering LDL-C and preventing major adverse cardiovascular events (“MACE”).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.